A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial
The current standard treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma (DLBCL) primarily consists of intensified salvage therapy and, if the disease is chemo-sensitive, high dose therapy followed with autologous stem cell transplantation. In the rituximab era howev...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
25 June 2013
|
| In: |
BMC cancer
Year: 2013, Volume: 13, Pages: 1-5 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-13-308 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-13-308
|
| Author Notes: | Mathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling and Georg Hess |
| Summary: | The current standard treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma (DLBCL) primarily consists of intensified salvage therapy and, if the disease is chemo-sensitive, high dose therapy followed with autologous stem cell transplantation. In the rituximab era however, this treatment approach has shown only limited benefit. In particular, patients relapsing after rituximab-containing primary treatment have an adverse prognosis, especially if this occurs within the first year after therapy or if the disease is primarily refractory. Therefore there is an ultimate need for improved salvage treatment approaches. |
|---|---|
| Item Description: | Gesehen am 18.11.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/1471-2407-13-308 |